Merck eye drug matches anti-VEGF in DME trial with safety caveats
Merck (MRK) reported one-year results from its BRUNELLO trial for remigromig, an investigational drug for diabetic macular edema (DME). Both doses met the primary endpoint, showing non-inferiority to ranibizumab in visual acuity improvement. However, adverse events related to proliferative diabetic retinopathy were more frequent with remigromig. Merck plans to discuss results with regulators and is conducting further analyses.
How this was made
The 30-second read
Why it matters
The non‑inferior efficacy positions remigromig as a possible alternative to anti‑VEGF therapy, but safety signals may temper enthusiasm.
Market read
First disclosure of pivotal trial results for a major pharma player; could affect MRK stock and ophthalmology biotech sector.
What to watch
Potential for regulatory scrutiny over higher PDR rates and need for longer‑term data.
Background
Merck presented the data at the American Academy of Ophthalmology meeting, highlighting its novel tri‑specific antibody.
Ticker impact
Merck reported Phase 2b/3 BRUNELLO trial data showing remigromig met primary endpoint with non‑inferior visual acuity gains versus ranibizumab.
potential modest pressure as investors weigh safety concerns against efficacy
First‑time disclosure of pivotal trial results; efficacy is positive but safety signals may limit upside.
Market effects
May influence other ophthalmology biotech peers as a Wnt‑pathway approach gains data.
Limited to US biotech and pharma markets.
Modest, primarily affecting investors tracking ophthalmology drug pipelines.
Counterpoint
Safety concerns could outweigh efficacy, prompting a sell‑off if adverse events rise.
Key entities
- companyMerck
Pharmaceutical company conducting the trial.
- drugremigromig
Investigational tri‑specific antibody targeting the Wnt pathway.
